Characteristics of gastric neuroendocrine tumors and the PDX-1 transcription factor expression

Close metadata

OBJECTIVE

To study the features of gastric neuroendocrine tumors (NETs) and the diagnostic and prognostic significance of PDX-1 expression in them.

MATERIAL AND METHODS

207 NETs identified in 56 men and 115 women (59 had multiple NETs), and 94 cases of gastric cancer (comparison group) were studied morphologically and immunohistochemically.

RESULTS

In more than half of the cases (54.93%), NETs were localized in the body of the stomach; the cardiac and antral parts of the stomach accounted for 8.64% and 11.73%, respectively. NETs of the cardiac region predominated in men, and of the body and antrum — in women. NETs of the cardiac region predominated in men, and of the body and antrum — in women. The vast majority of NETs were highly differentiated (89.20%), of which Grade 1, 2 and 3 were 55.41%, 40.76% and 3.82%, respectively. Neuroendocrine carcinomas (NEC) accounted for 10.80% of all NET cases. NECs were more often localized in the cardiac part of the stomach and accounted for 35.71% of all NETs in the cardiac part. The share of NEC among all NETs of the antrum was 15.79%, of the body of the stomach — only 3.37%. Metastases were found in 17.90% of NETs. Expression of PDX-1 was detected in 44.73% of NETs, 70% of NECs and 74.50% of gastric cancers.

CONCLUSION

PDX-1 is involved in the mechanisms of precancerous and cancerous lesions of the stomach and its overexpression is detected in the majority of the most malignant NETs and gastric cancers.

Keywords:

gastric neuroendocrine tumors

location

type

Grade

transcription factor PDX-1 expression

prognosis

Authors:

Gurevich L.E.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)

ORCID: 0000-0002-9731-3649

Vasyukova O.A.

Avtsyn Research Institute of Human Morphology of «Petrovsky National Research Centre of Surgery»

ORCID: 0000-0001-6068-7009

Mikhaleva L.M.

A.P. Avtsyn Research Institute of Human Morphology

ORCID: 0000-0003-2052-914X

Bondarenko E.V.

M.F. Vladimirsky Moscow Regional Research Clinical Institute;
Endocrinology Research Centre

ORCID: 0000-0003-2122-2297

Shikina V.E.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

ORCID: 0000-0002-6672-4269

Received:

24.10.2023

Accepted:

28.02.2024

List of references:

Panzuto F, Campana D, Massironi S, Faggiano A, Rinzivillo M, Lamberti G, Sciola V, Lahner E, Manuzzi L, Colao A, et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: a multicentre retrospective study. Dig Liver Dis. 2019;51(10):1456-1460. https://doi.org/10.1016/j.dld.2019.04.016
Sackstein PE, O’Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45(4):249-258. https://doi.org/10.1053/j.seminoncol.2018.07.001
WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Digestive system tumours. 5th ed. Vol. 1. France, Lyon: International Agency for Research on Cancer; 2019. https://tumourclassification.iarc.who.int
La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67(11):938-948. https://doi.org/10.1136/jclinpath-2014-202515
Algashaamy K, Garcia-Buitrago M. Multifocal G1-G2 gastric neuroendocrine tumors: differentiating between Type I, II and III, a clinicopathologic review. World J Clin Cases. 2019;7(17):2413-2419. https://doi.org/10.12998/wjcc.v7.i17.2413
Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735-752. https://doi.org/10.1097/MPA.0b013e3181ebb168
Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol. 2009;15(18):2177-2183. https://doi.org/10.3748/wjg.15.2177
Exarchou K, Stephens NA, Moore AR, Howes NR, Pritchard DM. New developments in gastric neuroendocrine neoplasms. Curr Oncol Rep. 2022;24(1):77-88. https://doi.org/10.1007/s11912-021-01175-y
La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373-1384. https://doi.org/10.1016/j.humpath.2011.01.018
Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morthological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85-93. https://doi.org/10.1159/000445165
Ma J, Chen M, Wang J, Xia HH, Zhu S, Liang Y, Gu Q, Qiao L, Dai Y, Zou B, et al. Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer. Carcinogenesis. 2008;29(7):1327-1333. https://doi.org/10.1093/carcin/bgn112
Buettner M, Dimmler A, Magener A, Brabletz T, Stolte M, Kirchner T, Faller G. Gastric PDX-1 expression in pancreatic metaplasia and endocrine cell hyperplasia in atrophic corpus gastritis. Mod Pathol. 2004;17(1):56-61. https://doi.org/10.1038/modpathol.3800015
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. https://doi.org/10.1001/jamaoncol.2017.0589
Calvete O, Reyes J, Zuñiga S, Paumard-Hernández B, Fernández V, Bujanda L, Rodriguez-Pinilla MS, Palacios J, Heine-Suñer D, Banka S, et al. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum Mol Genet. 2015;24(10):2914-2922. https://doi.org/10.1093/hmg/ddv054
Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res. 2010;162(1):22-25. https://doi.org/10.1016/j.jss.2010.01.005
Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, Maasberg S, Wiedenmann B, Pavel M, Pascher A, et al. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer. 2019;26(9):751-763. https://doi.org/10.1530/ERC-18-0582
Lawrence B, Kidd M, Svejda B, Modlin I. A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep. 2011;13(1):101-109. https://doi.org/10.1007/s11894-010-0158-4
Vanoli A, La Rosa S, Miceli E, Klersy C, Maragliano R, Capuano F, Persichella A, Martino M, Inzani F, Luinetti O, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology. 2018;107(2):114-126. https://doi.org/10.1159/000489902
Han D, Li YL, Zhou ZW, Yin F, Chen J, Liu F, Shi YF, Wang W, Zhang Y, Yu XJ, et al. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms. World J Gastroenterol. 2021;27(21):2895-2909. https://doi.org/10.3748/wjg.v27.i21.2895
Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol. 2017;23(3):516-524. https://doi.org/10.3748/wjg.v23.i3.516
Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, Katai H, Tsuda H, Kushima R. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37(7):949-959. https://doi.org/10.1097/PAS.0b013e31828ff59d
Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol. 2006;30(8):945-953. https://doi.org/10.1097/00000478-200608000-00003
Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med. 1998; 122(11):1010-1017.
Leys CM, Nomura S, Rudzinski E, Kaminishi M, Montgomery E, Washington MK, Goldenring JR. Expression of Pdx-1 in human gastric metaplasia and gastric adenocarcinoma. Hum Pathol. 2006;37(9):1162-1168. https://doi.org/10.1016/j.humpath.2006.04.011
Buettner M, Dimmler A, Magener A, Brabletz T, Stolte M, Kirchner T, Faller G. Gastric PDX-1 expression in pancreatic metaplasia and endocrine cell hyperplasia in atrophic corpus gastritis. Mod Pathol. 2004;17(1):56-61. https://doi.org/10.1038/modpathol.3800015
Sakai H, Eishi Y, Li XL, Akiyama Y, Miyake S, Takizawa T, Konishi N, Tatematsu M, Koike M, Yuasa Y. PDX1 homeobox protein expression in pseudopyloric glands and gastric carcinomas Gut. 2004;53(3):323-330. https://doi.org/10.1136/gut.2003.026609
Oz Puyan F, Can N, Ozyilmaz F, Usta U, Sut N, Tastekin E, Altaner S. The relationship among PDX1, CDX2, and mucin profiles in gastric carcinomas; correlations with clinicopathologic parameters. J Cancer Res Clin Oncol. 2011;137(12):1749-1762. https://doi.org/10.1007/s00432-011-1044-7
Gurevich LE, Proshchina AE, Voronkova IA, Ashevskaya VE, Korosteleva PA, Dolzhanskii OV. Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs. Arkhiv Patologii. 2019;81(5):11-21. (In Russ.). https://doi.org/10.17116/patol20198105111
Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. PDX1 associated therapy in translational medicine. Ann Transl Med. 2016;4(11):214. https://doi.org/10.21037/atm.2016.03.51
Zhou G, Sinnett-Smith J, Liu SH, Yu J, Wu J, Sanchez R, Pandol SJ, Abrol R, Nemunaitis J, Rozengurt E, et al. Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin. Front Physiol. 2014;5:226. https://doi.org/10.3389/fphys.2014.00226

Close metadata